Maxzide Drug Classification
Maxzide is a combination diuretic containing a potassium-sparing diuretic (triamterene) and a thiazide-type diuretic (hydrochlorothiazide). 1, 2
Components and Mechanism
Maxzide contains two distinct diuretic agents working on different parts of the nephron:
Triamterene (75 mg): A potassium-sparing diuretic that inhibits the epithelial sodium channel (ENaC) in the cortical collecting duct, reducing potassium secretion while promoting sodium excretion 3
Hydrochlorothiazide (50 mg): A thiazide-type diuretic (benzothiadiazine derivative) that acts on the distal convoluted tubule 2
The 2025 AHA/ACC hypertension guidelines classify hydrochlorothiazide as a thiazide-type diuretic, grouping it with chlorthalidone and indapamide under a single umbrella term for simplicity, despite chemical structure differences 4.
Pharmacodynamic Interaction
The combination provides additive blood pressure lowering through sequential nephron blockade, with each drug acting on different tubular segments 5. Research demonstrates that triamterene enhances the antihypertensive effect of hydrochlorothiazide by an additional 3.8 mmHg systolic reduction beyond hydrochlorothiazide alone 3. This additive effect is pharmacodynamic rather than pharmacokinetic—the drugs do not alter each other's renal excretion 5.
Clinical Context
The potassium-sparing component prevents the hypokalemia commonly associated with thiazide monotherapy, making this combination particularly useful for patients requiring diuretic therapy who cannot risk electrolyte depletion 6. The 2025 guidelines note that potassium-sparing diuretics can stimulate both renin and aldosterone, which is relevant when screening for secondary causes of hypertension 4.
Critical Contraindication
Maxzide is absolutely contraindicated with other potassium-sparing agents (spironolactone, amiloride, eplerenone) or potassium supplements, as two deaths have been reported with concomitant spironolactone and triamterene use 1.